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Abstract Determining the eligibility of patients with
Parkinson’s disease (PD) for deep brain stimulation (DBS)
can be challenging for general (non-specialised) neurolo-
gists. We evaluated the use of an online screening tool
(Stimulus) that aims to support appropriate referral to a
specialised centre for the further evaluation of DBS.
Implementation of the tool took place via an ongoing
European multicentre educational programme, currently
completed in 15 DBS centres with 208 referring
neurologists. Use of the tool in daily practice was moni-
tored via an online data capture programme. Selection
decisions of patients referred with the assistance of the
Stimulus tool were compared to those of patients outside
the screening programme. Three years after the start of the
programme, 3,128 patient proﬁles had been entered. The
intention for referral was made for 802 patients and referral
intentions were largely in accordance with the tool rec-
ommendations. Follow-up at 6 months showed that actual
referral took place in only 28%, predominantly due to
patients’ reluctance to undergo brain surgery. In patients
screened with the tool and referred to a DBS centre, the
acceptance rate was 77%, signiﬁcantly higher than that of
the unscreened population (48%). The tool showed a sen-
sitivity of 99% and a speciﬁcity of 12% with a positive and
negative predictive value of 79 and 75%, respectively. The
Stimulus tool is useful in assisting general neurologists to
identify appropriate candidates for DBS consideration. The
principal reason for not referring potentially eligible
patients is their reluctance to undergo brain surgery.
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Introduction
Deep brain stimulation (DBS) is an established therapy for
patients with advanced Parkinson’s disease (PD). Several
clinical trials have demonstrated signiﬁcant improvement of
motor symptoms, daily ‘off’ time, medication use and
quality of life in well-selected patients [1–10]. To determine
eligibility for DBS, patients need to undergo a compre-
hensive assessment in a specialised centre for movement
disorders. Partly due to the lack of clear and manageable
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stantial proportion of patients are rejected following the
evaluation in DBS centres [11]. For the same reason, it is
also conceivable that many patients who could beneﬁt from
DBS therapy are not referred for further evaluation. In order
to support appropriate pre-selection, we developed and
implemented an online screening tool, called Stimulus, and
monitored its use in daily clinical practice. The monitoring
project aims at determining the relationship between the
tool recommendations and actual referral decisions, as well
as the predictive value of the tool outcomes for ﬁnal
selection decisions in specialised DBS centres. Here we
present the three-year results of this ongoing project.
Methods
Electronic screening tool
The development of the electronic screening tool is
described elsewhere [12]. In summary, a panel of 12
European experts in movement disorders used the RAND
Appropriateness Method [13, 14] to assess the appropri-
ateness of referral for DBS for 972 hypothetical patient
proﬁles. These proﬁles were mutually exclusive combina-
tions of the values of seven clinical variables considered
relevant to the decision as to whether a patient should be
referred to a specialised centre for the consideration of
DBS. Variables included age, disease duration, severity of
off-symptoms, dyskinesias and tremor, presence of axial
symptoms, and mental status. During a two-round process,
panelists individually rated the appropriateness of referral
using a nine-point scale. For each of the proﬁles included,
an appropriateness statement (appropriate, inappropriate, or
uncertain) was calculated on the basis of the median panel
score and the extent of agreement [14]. The panel also
formulated ﬁve absolute criteria a patient should meet to be
considered for further DBS evaluation (diagnosis of idio-
pathic Parkinson’s disease, presence of troublesome
symptoms despite optimal pharmacological treatment or
intolerable side effects of anti-parkinsonian medication,
motor improvement with levodopa, absence of medical
conditions preventing surgery, and absence of signiﬁcant
medically-resistant mental diseases). Panel results were
embedded in an electronic decision tool that allows the user
to select a patient proﬁle and to see the related panel rec-
ommendation on referral (Fig. 1). The Stimulus tool is
available via http://test.stimulus-dbs.org.
Fig. 1 User interface of the screening tool
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The tool was disseminated via regional educational meet-
ings for general neurologists in six European countries.
Meetings were moderated by an expert in movement dis-
orders from the same region, and included an explanation
of the development and functionalities of the tool. After the
meeting, participants were asked to use the tool consecu-
tively for a period of 4 months in patients having trou-
blesome symptoms from Parkinson’s disease. The tool
recommendation was not mandatory for the referral deci-
sion. Patient proﬁles and referral decisions were anony-
mously entered by participating neurologists in an online
database. Six months after initial data entry, they were
asked to add follow-up data for all patients for whom a
positive referral intention was documented (veriﬁcation of
actual referral; if not referred, reasons behind the decision).
For patients referred to a specialised centre for the con-
sideration of DBS treatment, neurologists were asked to
attach a printed tool report to the referral letter (see Fig. 2).
Evaluation
In parallel with the data collection by general neurologists,
regional DBS centres were asked to provide monthly
reports on ﬁnal selection decisions (acceptance/refusal,
reasons for refusal) for all PD patients evaluated for DBS
(Fig. 2). Using the form attached to the referral letter, a
distinction could be made between patients referred with
and without the use of the Stimulus tool. For patients with a
completed screening form, appropriateness data were
added to information about the ﬁnal selection decision.
Data analysis
The association between tool recommendations and refer-
ral intentions was studied by cross-tabulation (v
2 test). The
same statistical approach was used to analyse differences in
acceptance rates of patients screened or not screened by the
tool. The predictive value of the tool recommendations
(inappropriate versus appropriate/uncertain) was assessed
using the common measures for diagnostic tests (sensitiv-
ity, speciﬁcity, positive and negative predictive value). To
study differences in the reasons for refusal between
screened and unscreened patients, the Fisher’s exact test
was applied.
Standard protocol approvals, registrations, and patients
consents
All patient data were anonymously entered in the database.
Participants were instructed that the tool outcome (panel
recommendation) should in no way interfere with their
independent judgment and referral decision. The need for
ethical approval differed by national regulations. In Spain,
approval was obtained from the Andalusian Health Coun-
cil, while in Germany no explicit requirements were con-
sidered to apply for this type of data collection.
PD patients having troublesome symptoms
( 3 128)
All PD patients referred for
DBS id ti ( 791)
General neurologists DBS centres
(n=3,128) DBS consideration (n=791)
Absolute Not fulfilled
(n=539)
Fulfilled
Inappropriate (n=896)
criteria (n 539) 
STOP
(n=2,589
Uncertain (n=1,116)
Appropriate (n=577)
Tool recommendation
Negative (n=1,787)
STOP
Referral intention Positive (n=802)
Not referred (n=577)
Non-STIMULUS patients 
(n=567)
Actual referral
(follow-up at 6 months)
Referred via STIMULUS
(n=224)*
Treatment decision (DBS centres) Accepted
(n=173)
Refused
(n=51)
Accepted
(n=270)
Refused
(n=297)
*1 patient lost to follow-up
Fig. 2 Flow chart of the data
collection by general
neurologists and by DBS
centres
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Since February 2007, the programme has run in six Euro-
pean countries involving 29 DBS centres and surrounding
regions. Currently, more than 4,000 patient proﬁles have
been entered in the online database. In the remainder of this
section, we will restrict our discussion to regions and
centres for which data collection has been entirely com-
pleted (14 regions/centres in Germany and 1 in Spain). The
educational meetings were attended by around 250 neu-
rologists, the majority (n = 208) of whom agreed to par-
ticipate in the monitoring programme. As of February
2010, 3,128 patient proﬁles had been completed (mean: 15
patients per participating neurologist). Five-hundred and
thirty-nine patients (17%) did not meet the absolute
requirements of DBS consideration (ﬁrst check of the
screening tool). Of the remaining 2,589 patients, referral
was deemed appropriate in 22%, inappropriate in 35%, and
uncertain in 43%. The intention to refer a patient for DBS
consideration was strongly associated with the recom-
mendations on appropriateness made by the Stimulus
programme: a positive intention was documented in 73, 32
and 2% of patients with, respectively, an appropriate,
uncertain or inappropriate referral according to the tool
(Pearson v
2 = 830,613; P\0.0001). Six months after
initial data entry, 28% of patients for whom a positive
referral intention was documented had actually been
referred to a DBS centre. Principal reasons for not referring
a potentially appropriate candidate were the patient’s
reluctance to undergo brain surgery (50%) and patient
indecision (41%).
For the observational survey in the DBS centres, the
mean observation period was 16 months (range
6–24 months). Final selection decisions were documented
for 791 patients, of whom 224 (28%) had been screened
with the Stimulus tool (Table 1).
The acceptance rate of the Stimulus group was signiﬁ-
cantly higher than that of patients outside the screening
programme (77 vs. 48%; Pearson v
2 = 57,15; P\0.0001),
and was most favourable in patients for whom the outcome
of the tool was appropriate (83%). Of patients for whom
referral was deemed inappropriate by the tool (n = 8), two
were accepted for DBS.
Considering the Stimulus tool as a diagnostic test with
the outcome positive (appropriate or uncertain) or negative
(inappropriate), and taking the ﬁnal decision of the DBS
centres as the ‘gold standard’ (accepted/refused), the tool
showed a high sensitivity and a low speciﬁcity (Table 2).
The positive and negative predictive values were fairly
similar.
A comparison of reasons for refusal (by DBS centres)
between screened and unscreened patients is shown in
Table 3. In both groups, the top two categories were ‘anti-
parkinsonian medication not optimised yet’ and ‘neuro-
psychological and/or psychiatric disorders’, albeit their
frequency was higher in the Stimulus group. None of the
differences reached the level of statistical signiﬁcance
(Fisher’s exact test).
Discussion
Similar to observations in the United States [11], we found
that in patients referred by general neurologists without the
assistance of a screening tool, a substantial proportion
(52%) were refused for DBS after evaluation in a specia-
lised DBS centre. In patients for whom the Stimulus tool
was applied, the acceptance rate was signiﬁcantly higher
(77%), with most favourable ﬁgures in patients for whom
referral was deemed appropriate (83%). Taking the ﬁnal
selection decision by DBS centres as the reference value,
good to reasonable values were found for the tool’s sen-
sitivity (99%) and positive (79%) and negative (75%)
predictive value, while speciﬁcity was low (12%).
Although generally supporting the tool’s ability to improve
the quality of pre-selection for DBS, these results should be
considered within the context of the design and data col-
lection of this monitoring project.
Our focus was on the tool’s applicability in daily prac-
tice with a minimum burden for participating neurologists.
For that reason, data collection was limited and did not, for
Table 1 Acceptance for DBS (ﬁnal decisions by DBS centres) in
screened versus unscreened patients
Patient population Accepted for DBS
Number Percentage
Screened patients (n = 224) 173 77
Inappropriate (n = 8) 2 25
Uncertain (n = 62) 43 69
Appropriate (n = 154) 128 83
Unscreened patients (n = 567) 270 48
Table 2 Tool outcomes compared to ﬁnal selection decision by DBS
centres
Decision of DBS centre
Outcome Stimulus tool Accepted Refused Total
Appropriate/uncertain 171 45 216
Inappropriate 2 6 8
Total 173 51 224
Sensitivity: 99%; Speciﬁcity: 12%; Positive predictive value: 79%;
Negative predictive value: 75%
Absolute numbers of patients
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negative referral decision was made (potential false-nega-
tives). In addition, no follow-up data were collected for
these patients, and it is conceivable that some of them were
referred in a later phase.
Referral decisions were largely in line with the tool
recommendations, and resulted in a low number of inap-
propriate referrals (n = 8). The low speciﬁcity of the tool
(2 out of these 8 patients were eventually accepted for
DBS) should therefore be interpreted with caution.
Despite the strong association between panel recom-
mendations and referral ‘intentions’, only 28% of patients
for whom a positive intention was documented were
actually referred during the 6 month follow-up period. In
the vast majority of cases (90%) this was related to the
patients’ reluctance to undergo brain surgery or their wish
to postpone the decision of referral. However, it needs to be
considered that patients may change their decision over
time if the disease progresses and/or their conﬁdence in
DBS increases with further information. Therefore, it is
likely that a higher acceptance rate was found when the
follow-up period was longer.
Potential shortcomings of the tool may be reﬂected in
the reasons for refusal. For example, the principal reasons
for refusal in Stimulus patients were non-optimal anti-
parkinsonian medication and the presence of neuropsy-
chological and/or psychiatric disorders. Though not sig-
niﬁcantly different from the non-Stimulus patients
(presumably due to the low number of patients and events),
reﬁnement of these criteria by the inclusion of additional
checklists or screening tools may be warranted. However,
the beneﬁts of a more speciﬁc tool should be balanced
against the drawback of making it more time-consuming,
potentially jeopardising its use in routine neurological care.
Notwithstanding these considerations, we feel that the
diagnostic properties of the tool are sufﬁciently convincing
to advocate its use to assist general neurologists in deciding
on referral for DBS in patients with PD. Periodic reas-
sessment of the tool is needed in light of changing insights
and user experiences. For example, new insights into the
role of age [10, 15] and disease duration [16] for patient
selection may necessitate reconsideration of the criteria
included. We therefore consider the Stimulus tool as a
dynamic instrument of which the application could be
improved by a continuous process of learning from both
science and practice.
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Table 3 Reasons behind
refusal for DBS in patients
screened and not screened using
the Stimulus tool
Based on information from DBS
centres following evaluation
Principal reason for refusal Unscreened (n = 297) Screened (n = 51)
Number % Number %
Non-idiopathic PD 37 12 2 4
Insufﬁcient response to levodopa test 36 12 5 10
Anti-parkinsonian medication not optimised yet 68 23 17 33
Signiﬁcant levodopa-resistant axial symptoms 29 10 1 2
Motor disability not severe enough 27 9 6 12
Neuropsychological and/or psychiatric disorders 42 14 10 20
Abnormalities on brain imaging 2 1 1 2
Signiﬁcant co-morbidity 10 3 2 4
Contra-indication for surgery 1 \12 4
Poor motivation/unrealistic expectations patient 23 8 3 6
Other 21 7 2 4
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